Cantor Fitzgerald Issues Negative Outlook for DNTH Earnings

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimate for Dianthus Therapeutics from ($3.45) to ($3.53), while the consensus estimate is set at ($2.61) per share.
• Despite the EPS cut, seven investment analysts currently maintain a "buy" rating on Dianthus Therapeutics, with a consensus price target of $53.00.
• The company's most recent quarterly earnings report revealed a loss of ($0.88) EPS, missing analyst expectations by $0.02 and signaling a challenging financial outlook.

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Free Report) - Cantor Fitzgerald reduced their FY2025 earnings estimates for Dianthus Therapeutics in a research note issued on Monday, August 11th. Cantor Fitzgerald analyst P. Stavropoulos now expects that the company will earn ($3.53) per share for the year, down from their previous forecast of ($3.45). The consensus estimate for Dianthus Therapeutics' current full-year earnings is ($2.61) per share. Cantor Fitzgerald also issued estimates for Dianthus Therapeutics' FY2026 earnings at ($4.06) EPS.

Several other brokerages also recently commented on DNTH. William Blair initiated coverage on Dianthus Therapeutics in a research note on Wednesday, July 2nd. They set an "outperform" rating for the company. HC Wainwright reissued a "buy" rating and set a $40.00 target price on shares of Dianthus Therapeutics in a research note on Tuesday, May 13th. Finally, Robert W. Baird lowered their target price on Dianthus Therapeutics from $58.00 to $50.00 and set an "outperform" rating for the company in a research note on Tuesday, May 13th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $53.00.

Dianthus Therapeutics Trading Up 1.1%

NASDAQ DNTH traded up $0.22 during trading on Wednesday, hitting $20.96. 667,302 shares of the company's stock were exchanged, compared to its average volume of 320,571. The company has a market cap of $674.70 million, a PE ratio of -6.45 and a beta of 1.43. Dianthus Therapeutics has a fifty-two week low of $13.36 and a fifty-two week high of $32.27. The stock's 50 day moving average price is $19.49 and its two-hundred day moving average price is $19.98.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.86) by ($0.02). The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.87 million. Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Hudson Bay Capital Management LP increased its stake in shares of Dianthus Therapeutics by 53.9% in the second quarter. Hudson Bay Capital Management LP now owns 115,425 shares of the company's stock valued at $2,150,000 after buying an additional 40,425 shares during the period. Tower Research Capital LLC TRC increased its stake in shares of Dianthus Therapeutics by 330.7% in the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company's stock valued at $80,000 after buying an additional 3,317 shares during the period. Vestal Point Capital LP increased its stake in shares of Dianthus Therapeutics by 88.2% in the second quarter. Vestal Point Capital LP now owns 3,200,000 shares of the company's stock valued at $59,616,000 after buying an additional 1,499,931 shares during the period. Rafferty Asset Management LLC increased its stake in shares of Dianthus Therapeutics by 19.5% in the second quarter. Rafferty Asset Management LLC now owns 28,522 shares of the company's stock valued at $531,000 after buying an additional 4,650 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in Dianthus Therapeutics by 3,547.3% in the second quarter. BNP Paribas Financial Markets now owns 49,531 shares of the company's stock valued at $923,000 after acquiring an additional 48,173 shares during the last quarter. Institutional investors and hedge funds own 47.53% of the company's stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.